echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luoxin Pharmaceutical's Edaravone Injection passed the consistency evaluation of generic drugs

    Luoxin Pharmaceutical's Edaravone Injection passed the consistency evaluation of generic drugs

    • Last Update: 2022-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On January 9, Luoxin Pharmaceutical announced that its subsidiary Shandong Luoxin had recently received the "Approval Notice for Supplementary Drug Application" for Edaravone Injection approved and issued by the State Food and Drug Administration
    After review, the drug passed the consistency evaluation of generic drugs


    Edaravone injection is a brain protective agent (free radical scavenger), used to improve neurological symptoms, activities of daily living and functional impairment caused by acute cerebral infarction, and inhibit amyotrophic lateral sclerosis (ALS) caused by Progression of dysfunction

    Edaravone injection was first developed by Japan Tanabe Mitsubishi Pharmaceutical Co.
    , Ltd.
    , with the trade name of RADICUT® and the specification of 20ml: 30mg.
    It was launched in Japan on June 1, 2001, and the original formulation has not yet been launched in China

    The Edaravone injection developed by Shandong Luoxin was approved for the first time in June 2018, with the approval number: Guoyao Zhunzi H20183191


    According to IQVIA data, the global market size of edaravone injection in 2020 is 300 million US dollars (calculated at ex-factory price); according to IQVIA and Minet data, the domestic market size of edaravone injection in 2020 is 1.
    07 billion yuan (calculated in Tender price calculation)


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.